This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
by Zacks Equity Research
NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
NVSPositive Net Change IONSPositive Net Change ACIUPositive Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
by Zacks Equity Research
RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.
RAREPositive Net Change ALDXPositive Net Change ACIUPositive Net Change PGENNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
by Zacks Equity Research
Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
PGENNegative Net Change MRKPositive Net Change INOPositive Net Change
biotechs
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
by Zacks Equity Research
NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.
NVOPositive Net Change ALDXPositive Net Change ACIUPositive Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting
by Zacks Equity Research
LLY's Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales bolstering its cancer portfolio.
LLYPositive Net Change AZNPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
by Sundeep Ganoria
AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.
ABBVPositive Net Change BIIBNegative Net Change JNJPositive Net Change
biotechs medical pharmaceuticals
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
by Zacks Equity Research
SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.
REGNPositive Net Change SNYPositive Net Change AZNPositive Net Change
biotechs pharmaceuticals
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
by Zacks Equity Research
Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
BMYPositive Net Change CYTKNegative Net Change EWTXNegative Net Change
biotechnology biotechs pharmaceuticals
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
by Zacks Equity Research
Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.
LLYPositive Net Change NVOPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
by Zacks Equity Research
LQDA faces a major setback as a patent ruling threatens Yutrepia's PH-ILD indication and creates uncertainty around its commercial outlook.
LQDAPositive Net Change UTHRPositive Net Change INSMNegative Net Change
biotechnology biotechs medical pharmaceuticals